Compass Pathways (NASDAQ:CMPS) Raised to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Compass Pathways from “strong sell” to “sell,” while the broader analyst consensus remains “Moderate Buy” with a $23.36 target price.
• Compass Pathways shares rose 1.2% to open at $13.45, with a 52-week range of $3.97 to $15.40 and a market capitalization of approximately $1.82 billion.
• The company reported a quarterly loss of $1.88 per share, missing the consensus estimate of a $0.39 loss; institutional investors own 46.19% of the stock.

Compass Pathways (NASDAQ:CMPS - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "strong sell" rating to a "sell" rating in a report released on Sunday.

Several other equities research analysts have also recently issued reports on the company. Jefferies Financial Group reiterated a "buy" rating on shares of Compass Pathways in a research note on Tuesday, July 7th. Evercore upgraded Compass Pathways from an "in-line" rating to an "outperform" rating and set a $21.00 price objective on the stock in a research note on Wednesday, July 8th. Maxim Group upped their target price on Compass Pathways from $12.00 to $20.00 and gave the company a "buy" rating in a research report on Friday, May 15th. Oppenheimer reissued an "outperform" rating on shares of Compass Pathways in a report on Wednesday, August 5th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Compass Pathways in a research note on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Compass Pathways presently has an average rating of "Moderate Buy" and a consensus target price of $23.36.

Compass Pathways Stock Up 1.2%

NASDAQ:CMPS opened at $13.45 on Friday. Compass Pathways has a 52-week low of $3.97 and a 52-week high of $15.40. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30. The stock's fifty day moving average price is $12.63 and its two-hundred day moving average price is $9.56. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -2.91 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($1.49). On average, analysts anticipate that Compass Pathways will post -1.26 EPS for the current year.

Institutional Investors Weigh In On Compass Pathways

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ancora Advisors LLC bought a new position in shares of Compass Pathways in the 2nd quarter valued at $43,000. EverSource Wealth Advisors LLC lifted its position in shares of Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company's stock worth $26,000 after buying an additional 1,920 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in Compass Pathways in the fourth quarter valued at about $38,000. Caitong International Asset Management Co. Ltd acquired a new stake in Compass Pathways in the fourth quarter valued at about $47,000. Finally, Advisory Services Network LLC bought a new position in Compass Pathways in the third quarter valued at about $41,000. 46.19% of the stock is currently owned by institutional investors.

About Compass Pathways

Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source